A Food and Drug Administration (FDA) advisory panel has recommended loosening restrictions on several peptides, despite warnings from government scientists that evidence for their safety and effectiveness remains thin. For example, Market Research Future estimated the broader peptides market at $43.12 billion in 2024 and projected growth to $91.79 billion by 2035. What Are Peptides Safety Concerns? He also said the FDA reviews "establish that for all of the seven peptides the evidence for efficacy is either extremely thin or non-existent." "To begin with, experimental new drugs that lack evidence of efficacy or safety would not be presented to an FDA panel," Cohen said.